Evelo Bioscience is preparing for subjecting their groundbreaking therapy - relying on microbial strains - to tests conducted on humans. They are to serve the treatment of inflammatory processes and cancer. To this end, the company is planning to obtain USD 100 mln from public investors.
The company is developing orally-administered preparations containing microbial strains that may bring about a revolution to the treatment of many diseases. Evelo selects such strains from the point of view of the potential these micro-organisms have for interaction with the immune cells of their host that can be found inside one's intestines. Due to this, it may become possible to adjust the immune response of the organism along many paths. What is more, the use of strains that naturally occur in humans is supposed to ensure good tolerability of this therapy.
Evelo has already been given an authorisation for commencing the clinical trials of EDP1066 in patients suffering from mild/ moderate psoriasis and atopic dermatitis. If the research turns out to be successful, it is also planned to test EDP1815 therapy with regard to the rheumatoid arthritis and inflammatory bowel disease, as followed by EDP1503 therapy targeted at colorectal cancer, melanoma or recurrences of PD-1. For the purposes of these clinical trials, the company will use capsules that could not be used during tests carried out on mice. Evelo is expecting the bacterial strain to get through the bowel tissue, while it is true today that no dosage regimen that could ensure sufficient immune activity has been developed yet.